Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMDW 57 EV-to-OCF is 0.00 as of Sep. 09, 2026. GuruFocus rates BTMDW with a GF Score™ of 57/100. The stock has 2 warning signs investors should review. Among 682 Healthcare Providers & Services companies, Biote ranks better than 56.6% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Biote's Enterprise Value is $0.00 Mil.
Biote's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $24.37 Mil. Therefore, Biote's EV-to-OCF for today is 0.00.
The historical rank and industry rank for Biote's EV-to-OCF or its related term are showing as below:
BTMDW'
s EV-to-OCF Range Over the Past 10 Years
Min: -35.58 Med: 4.95 Max: 14.96
Current: 6.91
During the past 7 years, the highest EV-to-OCF of Biote was 14.96. The lowest was -35.58. And the median was 4.95.
BTMDW's EV-to-OCF is ranked better than 56.6% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 8.72
vs BTMDW: 6.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-09), Biote's stock price is $1.61.
Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.000. Therefore, Biote's PE Ratio (TTM) for today is N/A.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biote's share price for today is $1.61.
Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biote EV-to-OCF Related Terms
Biote EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Biote's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Biote's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Biote's EV-to-OCF falls into.
Biote's current Enterprise Value is $0.00 Mil.
Biote's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMDW) has a EV-to-OCF of 0.00 as of Sep. 09, 2026. According to the industry distribution chart, Biote ranks #296 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 43.4%.
Is Biote's EV-to-OCF too high?
Biote's current EV-to-OCF is 0.00. Based on the distribution chart, Biote ranks #296 out of 682 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Biote has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Biote's EV-to-OCF compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #296 out of 682 companies for EV-to-OCF. This puts Biote in the upper half of its industry. The industry median EV-to-OCF is 8.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.72, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Biote (BTMDW) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Biote's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Biote (BTMDW), the current EV-to-OCF is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
57GF Score
Get the complete analysis for BTMDW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMDW has been successfully added to your 
